Dilli Ram Poudel1, Prakash Acharya2, Sushil Ghimire1, Rashmi Dhital3, Rajani Bharati4. 1. Department of Internal Medicine, Reading Health System, West Reading, PA, USA. 2. Department of Internal Medicine, Montefiore New Rochelle, New Rochelle, NY, USA. 3. Department of Internal Medicine, Universal College of Medical Sciences, Bhairahawa, Nepal. 4. School of Public Health and Health Policy, City University of New York, New York, NY, USA.
Abstract
PURPOSE: Adverse drug events (ADEs) represent medication-related patient harm, which is associated with significant patient morbidity and mortality. This study was conducted to determine the rate, specific causes, and outcomes of ADE-related hospitalization in the USA. METHODS: We used the Healthcare Cost and Utilization Project's Nationwide Inpatient Sample dataset for the years 2008 to 2011. We selected patients with ADE based on 537 Classification of Diseases-9 codes. Main outcome measures included yearly prevalence, cost, length of stay, and mortality of ADE-related hospitalizations. Calculations were performed on weighted samples, and statistical significance was set at p-value <0.05 (two-tailed). RESULTS: We estimated the total hospitalizations with ADE to be 9 440 757 patients (6.28% of total) from 2008 to 2011. Increasing trend was noted from 2008 (5.97%) to 2011 (6.82%) with an annual percentage change rate of 4.37. Patients with ADE were significantly older (2011: mean age 61.42 vs. 48.65 years) and had more comorbidities. Steroids (14.49%), antineoplastic drugs (13.06%), anticoagulants (11.33%), nonsteroidal anti-inflammatory drugs (8.78%), and opiates/narcotics (6.48%) were the five most common causes of ADE. Patient with ADE stayed 1.89 days [95% confidence interval (CI) (1.79-1.99); p < 0.001] longer, incurred $1851.44 [95%CI ($1613.90-$2088.96), p < 0.001] higher with higher odds of mortality 1.27 [95%CI (1.24-1.29), p < 0.001]. CONCLUSION: Adverse drug event carries a significant burden of inpatient hospital care, incurs more cost, and leads to increased loss of life. Targeted policies to reduce them could potentially help decrease mortality as well as drive down cost.
PURPOSE: Adverse drug events (ADEs) represent medication-related patient harm, which is associated with significant patient morbidity and mortality. This study was conducted to determine the rate, specific causes, and outcomes of ADE-related hospitalization in the USA. METHODS: We used the Healthcare Cost and Utilization Project's Nationwide Inpatient Sample dataset for the years 2008 to 2011. We selected patients with ADE based on 537 Classification of Diseases-9 codes. Main outcome measures included yearly prevalence, cost, length of stay, and mortality of ADE-related hospitalizations. Calculations were performed on weighted samples, and statistical significance was set at p-value <0.05 (two-tailed). RESULTS: We estimated the total hospitalizations with ADE to be 9 440 757 patients (6.28% of total) from 2008 to 2011. Increasing trend was noted from 2008 (5.97%) to 2011 (6.82%) with an annual percentage change rate of 4.37. Patients with ADE were significantly older (2011: mean age 61.42 vs. 48.65 years) and had more comorbidities. Steroids (14.49%), antineoplastic drugs (13.06%), anticoagulants (11.33%), nonsteroidal anti-inflammatory drugs (8.78%), and opiates/narcotics (6.48%) were the five most common causes of ADE. Patient with ADE stayed 1.89 days [95% confidence interval (CI) (1.79-1.99); p < 0.001] longer, incurred $1851.44 [95%CI ($1613.90-$2088.96), p < 0.001] higher with higher odds of mortality 1.27 [95%CI (1.24-1.29), p < 0.001]. CONCLUSION: Adverse drug event carries a significant burden of inpatient hospital care, incurs more cost, and leads to increased loss of life. Targeted policies to reduce them could potentially help decrease mortality as well as drive down cost.
Authors: Adrian Wong; Diane L Seger; Kenneth H Lai; Foster R Goss; Kimberly G Blumenthal; Li Zhou Journal: J Allergy Clin Immunol Pract Date: 2018-12-01
Authors: Caterina Palleria; Luigi Iannone; Christian Leporini; Rita Citraro; Antonia Manti; Maurizio Caminiti; Pietro Gigliotti; Rosa Daniela Grembiale; Massimo L'Andolina; Giuseppe Muccari; Maria Diana Naturale; Domenico Olivo; Giuseppa Pagano Mariano; Roberta Pellegrini; Giuseppe Varcasia; Karim Abdalla; Emilio Russo; Francesco Ursini; Giovambattista De Sarro Journal: PLoS One Date: 2018-10-24 Impact factor: 3.240
Authors: Xi Yang; Jiang Bian; Ruogu Fang; Ragnhildur I Bjarnadottir; William R Hogan; Yonghui Wu Journal: J Am Med Inform Assoc Date: 2020-01-01 Impact factor: 4.497
Authors: Elisangela da Costa Lima; Thais de Barros Fernandes; Adair Freitas; Juliana Freire de Lima Sias; Marcelo Gerardin Poirot Land; Mariana Tschoepke Aires; Louise Bracken; Matthew Peak Journal: BMC Med Res Methodol Date: 2021-07-08 Impact factor: 4.615